Irinotecan (irinotecan): Reviews and patient testimonials

Irinotecan 20mg/ml concentrate for solution for infusion

Irinotecan hydrochloride is indicated for the treatment of patients with advanced colorectal cancer:

- in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,

- as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion

Irinotecan is indicated for the treatment of patients with advanced colorectal cancer.

• In combination with 5-fluorouracil (5-FU) and folinic acid (FA) in patients not having undergone previous chemotherapy for advanced cancer.

• As a single agent in patients who have not been successful with an established treatment regimen containing 5-FU.

Irinotecan in combination with Cetuximab is indicated for the treatment of patients with metastatic colorectal cancer (KRAS wild-type) with expression of epidermal growth factor receptor (EGFR) who have not received prior treatment for metastatic disease or after failure of a cytotoxic therapy that included Irinotecan.

Irinotecan in combination with 5-FU, FA and Bevacizumab is indicated as first-line treatment for patients with colon or rectum metastatic carcinoma.

Irinotecan in combination with a Capecitabine with or without Bevacizumab is indicated as first-line treatment for patients with metastatic colorectal carcinoma.

Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion

Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:

• in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,

• as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Irinotecan in combination with cetuximab it is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (please see 5.1).

Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Irinotecan in combination with capecitabine with or without bevacizumab it is indicated for first-line treatment of patients with metastatic colorectal carcinoma.

Irinotecan Hydrochloride Accord 20 mg/ml Concentrate for Solution for Infusion

Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of patients with advanced colorectal cancer:

• In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,

• As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild- type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy.

Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion in combination with Capecitabine with or without bevacizumab is indicated for first line treatment of patients with metastatic colorectal carcinoma.

Irinotecan Hydrochloride medac 20 mg/ml, concentrate for solution for infusion

Irinotecan Hydrochloride medac is indicated for the treatment of patients with advanced colorectal cancer

• as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

• in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.

Irinotecan Hydrochloride medac in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

Irinotecan Hydrochloride medac in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Route of administration: Injectable
Molecule: irinotecan